Histopathologic findings of eyes enucleated after treatment with chemosurgery for retinoblastoma

Open Ophthalmology Journal

Volumn 5, Issue , 2011, Pages 1-5

  Graeber, Carolyn P ^a,b   Gobin, Y Pierre ^a,c   Marr, Brian P ^a   Dunkel, Ira J ^a   Brodie, Scott E ^a,d   Bornfeld, Norbert ^e   Char, Devron H ^f   Folberg, Robert ^g   Imhof, Saskia M ^h   Lin, Amy Y ⁱ   Berry, Jesse L ^a,j   Mesfer, Saleh Al ^k   Moll, Annette C ^l   Abramson, David H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b EAR AND THROAT HOSPITAL   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d MOUNT SINAI HOSPITAL   (United States)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f STANFORD UNIVERSITY   (United States)

^g OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^j Research Development Test and Evaluation Division Code 524   (United States)

^k KING KHALED EYE SPECIALIST HOSPITAL   (Saudi Arabia)

^l VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Chemosurgery; Histopathology; Retinoblastoma

Indexed keywords

CARBOPLATIN; MELPHALAN; TOPOTECAN;

ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOSURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; ENUCLEATION; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; METASTASIS; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETINOBLASTOMA; TREATMENT RESPONSE; TUMOR CALCINOSIS; TUMOR NECROSIS; UNITED STATES; RETROSPECTIVE STUDY; SALVAGE THERAPY; TUMOR REGRESSION;

EID: 79955069475     PISSN: None     EISSN: 18743641     Source Type: Journal    
DOI: 10.2174/1874364101105010001     Document Type: Article

References (16)

1. Reese AB, Hyman GA, Tapley ND, Forrest AW. The treatment of retinoblastoma by x-ray and triethylene melamine. AMA Arch Ophthalmol 1958; 60: 897-906.
2. Kiribuchi M. Retrograde infusion of anti-cancer drugs to ophthalmic artery for intraocular malignant tumors. Nippon Ganka Gakkai Zasshi 1966; 70: 1829-33.
3. Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol 2004; 9: 69-73.
4. Ueda M, Tanabe J, Inomata M, Kaneko A, Kimura T. Study on conservative treatment of retinoblastoma--effect of intravitreal injection of melphalan on the rabbit retina. Nippon Ganka Gakkai Zasshi 1995; 99: 1230-5.
5. Kaneko A, Suzuki S. Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol 2003; 33: 601-7.
6. Suzuki S, Kaneko A. Management of intraocular retinoblastoma and ocular prognosis. Int J Clin Oncol 2004; 9:1-6.
7. Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 2008;115:1398-404.
8. Ohshima K, Kaneko T, Takagi S, Kaneko A, Yokouchi Y, Takeuchi S. Clinicopathological investigation of a retinoblastoma eye enucleated after vitreous surgery with melphalan perfusion. Jpn J Ophthalmol 2009; 53:186-8.
9. Balaguer J, Wilson MW, Billups CA, et al. Predictive factors of invasion in eyes with retinoblastoma enucleated after eye salvage treatments. Pediatr Blood Cancer 2009; 52: 351-6.
10. Kopelman JE, McLean IW, Rosenberg SH. Multivariate analysis of risk factors for metastasis in retinoblastoma treated by enucleation. Ophthalmology 1987; 94: 371-7.
11. Magramm I, Abramson DH, Ellsworth RM. Optic nerve involvement in retinoblastoma. Ophthalmology 1989; 96: 217-222.
12. Khelfaoui F, Validire P, Auperin A, et al. Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution. Cancer 1996; 77: 1206-13.
13. Shields CL, Shields JA, Baez K, Cater JR, De Potter P. Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors. Cancer 1994; 73: 692-8.
14. Kim JW, Kathpalia V, Dunkel IJ, Wong RK, Riedel E, Abramson DH. Orbital recurrence of retinoblastoma following enucleation. Br J Ophthalmol 2009; 93: 463-7.
15. Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol 2002; 120: 923-931.
16. Chantada GL, Dunkel IJ, de Davila MT, Abramson DH. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol 2004; 88: 1069-73.